Document is current
Any future updates will be listed below
-
Authors
Zhang, Xueyan
Chen, Chuxin
Fu, Yingjie
Wu, Haibin
Wang, Ning
Shi, Xinyi
Zhou, Yongjian
Duan, Yuyou
-
Funding
Funding for this research was provided by:
Foundation of Guangzhou Key Clinical Specialties (2024-2026)
Project of Key Medical Discipline in Guangzhou (2025-2027)
National Key Research and Development Program of China (2018YFA0108201)
Research Starting Funding of South China University of Technology (D6201880, K5180910, K5204120, and D6212440)
Research Starting Funding of the Second Affiliated Hospital of South China University of Technology (KY09060026)
Research Agreement between South China University of Technology and Guangzhou First People’s Hospital (D9194290)
- License Information
-
More Information
Article History
Received: 18 September 2025
Accepted: 28 January 2026
First Online: 30 January 2026
Declarations
:
: The authors declare no competing interests.
: This study was approved by the Ethics Committee of Guangzhou First people’s Hospital (Approval No.: K-2021–200, and approval date: December 12, 2021.) to use umbilical cord blood from healthy volunteers for Developing Differentiation System of Hematopoietic Stem/Progenitor Cells from Human Pluripotent Stem Cells and Function Validation of their Derivatives. The patients or their guardians/legally authorized representatives provided written informed consent for participation in the study with the use of umbilical cord blood. All mouse experiments were performed according to our experimental protocols approved by the Animal Ethics Committee of South China University of Technology University (Approval number: 2019073, and approval date: December 12, 2019.). WiCell Research Institute has confirmed that there was the ethical approval for collection of human embryonic stem cells (WA01(H1) and WA09(H9)) with NIH Approval NIHhESC-10–0043 and NIH Approval NIHhESC-10–0062, and that the donors had signed informed consent ( . org). We have confirmed that this study is reported in accordance with ARRIVE guidelines ( ).
: All authors consent for publication.
